Sickle Cell Disease
Etavopivat could offer ‘great benefit’ in sickle cell disease
SAN DIEGO — Etavopivat reduced the annualized vaso-occlusive crises rate vs. placebo for people with sickle cell disease, according to study data presented at ASH Annual Meeting and Exposition.
Hydroxyurea provides ‘remarkable clinical benefit’ in hemoglobin SC disease
SAN DIEGO — Hydroxyurea conferred benefit to children and adults with hemoglobin SC disease, according to study results presented at ASH Annual Meeting and Exposition.
Novel cell therapy ‘potentially life changing’ for people with sickle cell disease
SAN DIEGO — An investigational cell therapy reduced sickle hemoglobin and increased fetal and total hemoglobin for certain patients with sickle cell disease, according to results presented at ASH Annual Meeting and Exposition.
ASH presents honorific awards to ‘visionary’ hematologists
Several hematologists will be honored during this year’s ASH Annual Meeting.
ASH sickle cell disease research priorities address pain, organ dysfunction, drug development
American Society of Hematology has issued new sickle cell disease research priorities, highlighting seven key focus areas for maximum impact and benefit to patients.
Lactated Ringer solution superior to normal saline for sickle cell vaso-occlusive episodes
IV lactated Ringer solution should be the preferred volume-expanding fluid for resuscitation of patients with sickle cell disease who experience vaso-occlusive episodes at the time of hospital admission, according to study results.
‘Discouraging’ results show stroke incidence rising among people with sickle cell disease
Stroke rates among individuals with sickle cell disease have increased steadily over the last 25 years despite guidelines aimed at prevention, according to results of a retrospective study.
Consensus statement helps assess patient readiness for gene therapy in sickle cell disease
Patient readiness will greatly affect the success of gene therapy for sickle cell disease at the individual and collective levels, according to a consensus statement published in JAMA Network Open.
Lung function ‘stable’ 3 years after hematopoietic cell transplant in sickle cell disease
Patients with sickle cell disease who had non-myeloablative hematopoietic cell transplants had similar or better lung function 3 years later, according to results published in Annals of the American Thoracic Society.
National Sickle Cell Awareness Month: Guideline-concordant preventive care often lacking
September is National Sickle Cell Awareness Month.